ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC ), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009. IMUC’s President and Chief Executive Officer, Manish Singh, Ph.D., will present an overview of the company’s business and strategy at 1:45pm at the Island Hotel in Newport Beach.

A webcast of this presentation will be available live and by replay. To access both the live and archived webcasts, as well as the slide presentation used during the conference, please go to www.imuc.com

“We are very pleased to have been invited to present at this prestigious gathering of our region’s most promising up and coming companies,” commented Dr. Singh. ”We look forward to having the opportunity to reach a broader investor audience and expect that the occasion will help to significantly raise our exposure to investors who appreciate the type of growth oriented investment that our business presents.”

The conference brings together officers from 30 of Southern California's leading growth oriented companies operating across a breadth of enterprises, including the life sciences, technology, media, and real estate/financial industries with retail and institutional investors from all over the nation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Liraglutide activates key brain circuits to trigger weight loss in obesity